Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Progesterone gel - Juniper Pharmaceuticals

Drug Profile

Progesterone gel - Juniper Pharmaceuticals

Alternative Names: COL-1620; Crinone; Crinone 4%; Crinone 8%; Crinone8%; OneCrinone; Prochieve; Prochieve4%; Prochieve8%; progesterone vaginal gel 4%; progesterone vaginal gel 8%

Latest Information Update: 03 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia Laboratories
  • Developer Actavis; Allergan; Juniper Pharmaceuticals; Merck KGaA
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Amenorrhoea; Dysmenorrhoea; Female infertility; Menopausal syndrome; Menstruation disorders; Premenstrual syndrome
  • Discontinued Preterm labour

Most Recent Events

  • 03 Jul 2019 Progesterone gel is not yet available for Female infertility in Iceland and Slovenia
  • 03 Jul 2019 Launched for Female infertility in Bulgaria, Estonia, France, Latvia, Lithuania, Romania, Croatia prior July 2019 (Vaginal)
  • 08 Jan 2018 Juniper Pharmaceuticals extends the duration of its license and supply agreement with Merck KGaA for progesterone gel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top